https://socictopen.socict.org/files/original/417837fb981298cb5d92eb118bc3e20f.pdf 3510551d1caee8e6b0049b5f064d3fa2 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia Creator An entity primarily responsible for making the resource Yaseen M. Arabi, Ali H Hajeer, Thomas Luke, Kanakatte Raviprakash, Hanan Balkhy, Sameera Johani, Abdulaziz Al Dawood, Saad Alqahtani, Awad Al-Omari, Fahad Al Hameed, Frederick G. Hayden, Robert Fowler, Abderrezak Bouchama, Nahoko Shindo, Khalid Al-Khairy, Gail Carson, Yusri Taha, Musharaf Sadat, Mashail Alahmadi Description An account of the resource We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trials of convalescent plasma for passive immunotherapy of MERS-CoV infection may be feasible, but such trials would be challenging because of the small pool of potential donors with sufficiently high antibody titers. Alternative strategies to identify convalescent plasma donors with adequate antibody titers should be explored, including the sampling of serum from patients with more severe disease and sampling at earlier points during illness. Date A point or period of time associated with an event in the lifecycle of the resource 2016 Subject The topic of the resource Middle East respiratory syndrome coronavirus, MERS-CoV, Middle East respiratory syndrome, intensive care, convalescent plasma, high-titer convalescent plasma Identifier An unambiguous reference to the resource within a given context DOI: 10.3201/eid2209.151164 Source A related resource from which the described resource is derived Emerging Infectious Diseases Publisher An entity responsible for making the resource available Centers for Disease Control and Prevention Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Infectious and parasitic diseases, Medicine Language A language of the resource EN